Climb Bio (CLYM) announced the appointment of Douglas Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Dr. Williams previously served as the President of Research and Development at Sana Biotechnology (SANA) and was CEO of Codiak BioSciences.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLYM:
- Climb Bio to host investor day
- Climb Bio to Host Virtual Investor Event
- Climb Bio to provide budoprutug development strategy at virtual investor event
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
